Highlights

  • Racura Oncology commenced patient dosing in the HARNESS-1 Phase 1a/b trial evaluating RC220 in lung cancer.
  • The trial is assessing RC220 in combination with AstraZeneca's Tagrisso (osimertinib) for EGFR-mutant non-small cell lung cancer.
  • The first patient received RC220 at 50mg/m² with no adverse events reported at the initial dose level.
  • Racura reported cash of approximately $34.3 million at the end of the June 2026 quarter.

Racura Oncology (ASX:RAC) has dosed its first patient in the HARNESS-1 clinical trial evaluating RC220 in combination with osimertinib for a genetically defined subset of lung cancer.

The announcement on 25 June 2026 marks the start of patient treatment in the Phase 1a/b study, which aims to assess the safety profile and early clinical signals of RC220 in patients with EGFR-mutant non-small cell lung cancer (NSCLC).

The first patient dosing milestone allows Racura (ASX:RAC) to begin generating clinical data from its oncology program, although the study remains at an early stage and is primarily designed to establish dose safety and tolerability.

What Was Announced?

Racura confirmed that the first patient had been treated in HARNESS-1, a multi-centre Phase 1a/b trial evaluating RC220, a proprietary formulation of (E,E)-bisantrene, in combination with osimertinib for patients with EGFR-mutant NSCLC.

EGFR mutations occur in a subset of lung cancer tumours and can make patients responsive to targeted therapies such as osimertinib. However, resistance can develop over time, creating a need for additional treatment approaches.

RC220 is designed as a small molecule that targets G-quadruplex DNA and RNA structures, with the company stating that this mechanism may help regulate MYC activity, a gene associated with cancer growth.

The first patient received RC220 through intravenous infusion at 50mg/m² on Day 1 of a 21-day cycle alongside standard-dose osimertinib. No adverse events were reported at the initial dose level.

The trial is being conducted at Monash Health in Clayton, Victoria, with Associate Professor Surein Arulananda as principal investigator.

The dose-escalation study will begin with patient cohorts at 50mg/m², followed by planned increases to 100mg/m² and 150mg/m². The Phase 1a portion is expected to enrol between 12 and 40 patients, followed by an approximately 40-patient Phase 1b expansion cohort.

Why This Matters

For Racura Oncology (ASX:RAC), first-patient dosing confirms that regulatory, ethics and trial infrastructure requirements have been completed, allowing the company to move from preclinical preparation into human clinical evaluation.

However, the milestone does not provide evidence that RC220 is effective. Phase 1a/b oncology trials are primarily designed to identify appropriate dose levels and evaluate safety.

The company reported no adverse events at the first dose level, although subsequent updates indicated that the first patient later developed Grade 2 colitis, with causation under review by the independent Safety Review Committee.

The committee recommended treating one further patient at the same 50mg/m² dose before progressing dose escalation, reflecting a cautious approach commonly used in early oncology trials.

Company Background

Racura Oncology (ASX:RAC) is an ASX-listed clinical-stage oncology company developing small molecule cancer therapies.

The company's pipeline includes RC220, alongside a Phase 3 program in acute myeloid leukaemia (AML) and an earlier-stage Phase 1a/b combination study involving doxorubicin in solid tumours.

Racura has research collaborations with institutions including Astex, Emory University, Purdue University, MD Anderson Cancer Center, Sheba Medical Center, the University of North Carolina School of Medicine, the University of Wollongong and the University of Newcastle.

The company has stated that RC220 has composition-of-matter Patent protection extending for 20 years.

Financial Position

Racura reported cash of approximately $34.3 million at the end of the June 2026 quarter.

The company raised approximately $26.2 million during the quarter, including around $25.2 million from conversion of piggyback Options and a $1 million strategic Placement from a healthcare-focused institutional investor.

Racura stated that its cash position supports operations into calendar year 2028.

As a clinical-stage biotechnology company without product revenue, Racura continues to rely on available cash resources to fund clinical development programs.

What Comes Next?

The immediate focus for Racura (ASX:RAC) is continued dose escalation within HARNESS-1.

The Safety Review Committee will assess safety information from additional patients treated at the initial 50mg/m² dose before any progression to higher dose levels.

The company has also indicated plans to open additional clinical trial sites to support recruitment.

Beyond HARNESS-1, investors will monitor progress across Racura's Phase 3 AML program and the separate doxorubicin combination study.

Risks

Racura (ASX:RAC) remains exposed to early-stage oncology development risks, including potential dose-limiting toxicities, uncertain efficacy outcomes and delays in clinical progression. The colitis event in the first patient remains under review and highlights the need for continued safety monitoring. There is no guarantee RC220 will progress to later-stage trials, receive regulatory approval or demonstrate clinical benefit. As a clinical-stage company without product revenue, Racura also remains dependent on cash reserves and future funding requirements.

Investor Takeaway

Racura has reached an important operational milestone by dosing the first patient in the HARNESS-1 trial, allowing RC220 to enter human clinical testing in EGFR-mutant NSCLC.

The company has strengthened its Balance Sheet with funding extending its reported runway into 2028, providing support for ongoing clinical programs.

However, the current data remains limited to early-stage safety assessment. The next important indicators will be Safety Review Committee decisions, dose escalation progress and future clinical data from HARNESS-1.